ZYBERNO
Stock Report
Updated Aug 31, 2026

GOSSAMER BIO, INC. (GOSS)

Healthcare • NASDAQ

$0.17

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
GOSSAMER BIO, INC. (GOSS) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-311.7%)
Return on Capital (Capital Efficiency):CRITICAL (-348.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

GOSSAMER BIO, INC. (GOSS) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, GOSS generated -$170.27M in Owner Earnings. Capital was deployed as follows: $53.00K invested in capital expenditures. Reinvestment rate: 0.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.17
Market Cap:$54.40M

Valuation Multiples (2)

P/S Ratio:1.02x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$17.18M

Price Action & Momentum (1)

% of 52-Week High:4.4%
B. Profitability Assessment

Return Metrics (4)

ROA:-85.4%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.2%

Margin Analysis (3)

Operating Margin Ttm:-311.7%
Net Margin Ttm:-235.0%
Ebitda Margin:-311.7%

TTM Performance (2)

Operating Margin Ttm:-311.7%
Net Margin Ttm:-235.0%

Yield Metrics (2)

Earnings Yield:-$411.04
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-220.0%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):17.5%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.53x
Quick Ratio:0.53x
Cash Ratio:0.30x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-15.58x
Times Interest Earned:-15.58

Capital Structure (4)

Working Capital:-65,058,000.00
Cash And Cash Equivalents:41,148,000.00
Long Term Debt:$2.96M
Net Debt:-$37.23M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $53.29M
Linear Growth: 17.5%
📊 Click to view full GOSS Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$166.09M

Bottom Line Performance (3)

-$125.22M
Income Before Tax:-$64.76M
Ebitda Ttm:-166,070,000.00

Operating Expenses (5)

Operating Expenses:219,379,000.00
R And D Expense:163,964,000.00
Sga Expense:47,940,000.00
Income Tax Expense:$3.30M
Interest Expense:10,959,000.00

Expense Ratios (3)

R And D To Revenue Percentage:1,774.9%
Sga To Revenue Percentage:518.9%
Ebitda Margin:-311.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$76.87M
Current Assets:$72.73M
Ppe Net:55,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:170,896,000.00
Current Liabilities:137,783,000.00
Long Term Debt:$2.96M
Short Term Debt:$965.00K

Equity & Capital (3)

Equity:-$94.03M
Retained Earnings:-$1.47B
Common Stock:700,000,000.00

Working Capital Items (3)

Accounts Receivable:6,105,000.00
Inventory:0.00
Accounts Payable:5,951,000.00

Special Items (2)

Contract Liabilities:7,068,000.00
Stock Based Compensation:2,463,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$170.26M-$170.32M

Investment Activities (2)

Investing Cash Flow:$41.61M
Capital Expenditures Ttm:53,000.00

Financing Activities (3)

Financing Cash Flow:$512.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:23,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.57
-$0.70
Earnings Per Share Ttm:-$0.39

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.17
Operating Cash Flow Per Share:-$0.54

Book Value & Capital (2)

Book Value Per Share:-$0.29
Cash Per Share:0.13

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.36x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:8.73x
Days Sales Outstanding Ttm:41.82

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:40.76
Cash Conversion Cycle:-997.95
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$170.27M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):17.5%

Other Growth Rates (1)

Book Value Growth Rate (Linear):2.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:GOSS
Company Name:GOSSAMER BIO, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:320.01M
Shares Outstanding Basic:320.01M
Shares Outstanding Diluted:328.78M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 21:37:15 UTC
Data Timestamp:2026-08-19T23:51:50.131176
Scroll to Top